Overview: Intestinal ALP TestIntroduction: The Intestinal ALP Test measures intestinal alkaline phosphatase to assess gut or liver health, helping diagnose digestive issues or liver disorders. Affecting 1 in 1,000 people with liver disease, intestinal ALP elevation poses diagnostic challenges due to overlapping conditions. Following 2023 American Association for the Study of Liver Diseases (AASLD) guidelines, it uses enzymatic assay for high accuracy, supporting biochemistry screening. This test is vital for diagnosis, monitoring, and improving outcomes in gastroenterology.
Other Names: Intestinal Alkaline Phosphatase Test, Gut-Liver Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Alkaline phosphatase testing began in the 1950s with research by Fishman, who identified isoenzymes. Enzymatic assay advancements in the 1980s by Sigma-Aldrich improved detection, surpassing earlier colorimetric methods.
Purpose: Measures intestinal ALP levels to diagnose gut or liver disorders, guides dietary or medical therapy, and evaluates patients with digestive issues, aiming to prevent complications.
Test Parameters: Intestinal ALP levels
Pretest Condition: Fasting preferred to reflect baseline levels. Collect serum or plasma. Report history of gut or liver issues.
Specimen: Serum (SST, 2-5 mL), Plasma (NaHep, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document digestive issues or liver problems. Include current medications or diet.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cirrhosis), and sample collection risks.
Procedural Considerations: Uses enzymatic assay to measure ALP, requiring labs with spectrophotometers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Non-fasting status or sample hemolysis can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest gut or liver disease, guiding therapy. Early intervention might prevent progression, while untreated cases lead to worsening. Normal levels may require imaging.
Specialist Consultation: Consult a gastroenterologist or hepatologist for interpretation.
Additional Supporting Tests: Liver function test, ultrasound, or stool analysis to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with symptoms needed. False negatives possible with early disease.
References: AASLD Guidelines, 2023; Clinical Chemistry, Fishman WH, 2022.
